Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03182257 · ClinicalTrials.gov registry record · Phase 1
Study of ONO-7579 in Patients With Advanced Solid Tumors/ NTRK Gene Fusion Positive Advanced Solid Tumors
A Phase 1 study, sponsored by Ono Pharmaceutical Co..
- Terminated
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT03182257 is a Phase 1 study that was terminated before completion, run by Ono Pharmaceutical Co.. The registered enrollment target is 1 participants.
The verdict
NCT03182257, a Phase 1 study, was terminated before completion, sponsored by Ono Pharmaceutical Co..
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
This study will determine the safety and maximum tolerated dose of ONO-7579 in patients with advanced solid tumors, and evaluate efficacy of ONO-7579 in patients with advanced solid tumors harboring NTRK gene fusions.
Interventions
- DRUG ONO-7579
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2017-07-12 |
| Est. Completion | 2018-01-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03182257
The ClinicalTrials.gov registry entry for NCT03182257 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ono Pharmaceutical Co., which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ONO-7579 is the first listed.
NCT03182257 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03182257 about?
NCT03182257 is a clinical study titled "Study of ONO-7579 in Patients With Advanced Solid Tumors/ NTRK Gene Fusion Positive Advanced Solid Tumors". This study will determine the safety and maximum tolerated dose of ONO-7579 in patients with advanced solid tumors, and evaluate efficacy of ONO-7579 in patients with advanced solid tumors harboring NTRK gene fusions.
What is the current status of trial NCT03182257?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2017-07-12. Estimated completion is 2018-01-30.
What interventions are being tested in trial NCT03182257?
The interventions under investigation include: ONO-7579 (DRUG).
Who is sponsoring clinical trial NCT03182257?
This trial is sponsored by Ono Pharmaceutical Co., which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.